Therapeutic agents useful for treating pain

Details Therapeutic agents useful for treating pain Therapeutic agents useful for treating pain

2007-08-14

2007-08-14

Bernhardt, Emily (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S360000

Reexamination Certificate

active

11368133

ABSTRACT:
A Compound of formula(wherein X is O or S and R1-R5are disclosed herein) or a pharmaceutically acceptable salt thereof (each being a “Piperazine Compound”), pharmaceutical compositions comprising a Piperazine Compound and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression in an animal comprising administering to an animal in need thereof an effective amount of a Piperazine Compound are disclosed.

REFERENCES:
patent: 4439606 (1984-03-01), Du et al.
patent: 4450272 (1984-05-01), Du et al.
patent: 5039680 (1991-08-01), Imperato et al.
patent: 5075341 (1991-12-01), Mendelson et al.
patent: 5198459 (1993-03-01), Imperato et al.
patent: 5232934 (1993-08-01), Downs
patent: 5430033 (1995-07-01), Cliffe et al.
patent: 5442064 (1995-08-01), Pieper et al.
patent: 5461047 (1995-10-01), Hansen, Jr. et al.
patent: 5556837 (1996-09-01), Nestler et al.
patent: 5556838 (1996-09-01), Mayer et al.
patent: 5574052 (1996-11-01), Rose et al.
patent: 5756504 (1998-05-01), Bock et al.
patent: 5762925 (1998-06-01), Sagen et al.
patent: 5780472 (1998-07-01), Cho et al.
patent: 5789412 (1998-08-01), Halazy et al.
patent: 5792768 (1998-08-01), Kulagowski et al.
patent: 5922872 (1999-07-01), Cook et al.
patent: 6028195 (2000-02-01), Cho et al.
patent: 6109269 (2000-08-01), Rise et al.
patent: 6124299 (2000-09-01), Baindur et al.
patent: 6204284 (2001-03-01), Beer et al.
patent: 6239267 (2001-05-01), Duckworth et al.
patent: 6329395 (2001-12-01), Dugar et al.
patent: 6335180 (2002-01-01), Julius et al.
patent: 6406908 (2002-06-01), McIntyre et al.
patent: 6723730 (2004-04-01), Bakthavatchalam et al.
patent: 2003/0153596 (2003-08-01), Suh et al.
patent: 2003/0158188 (2003-08-01), Lee et al.
patent: 2003/0158198 (2003-08-01), Lee et al.
patent: 1 014 116 (2000-06-01), None
patent: 1 122 242 (2001-08-01), None
patent: WO 96/21648 (1996-07-01), None
patent: WO 98/00402 (1998-01-01), None
patent: WO 98/25167 (1998-06-01), None
patent: WO 99/07672 (1999-02-01), None
patent: WO 99/37304 (1999-07-01), None
patent: WO 00/52001 (2000-09-01), None
patent: WO 02/05819 (2002-01-01), None
patent: WO 02/08221 (2002-01-01), None
patent: WO 02/16318 (2002-02-01), None
patent: WO 02/072536 (2002-09-01), None
patent: WO 02/076946 (2002-10-01), None
patent: WO 03/022809 (2003-03-01), None
patent: WO 03/062209 (2003-07-01), None
patent: WO 03/068749 (2003-08-01), None
Martinez, Mini Reviews in Medicinal Chemistry, vol. 3, pp. 718-718(1) (2003) (Abstract).
Valenzano et al. Current Medicinal Chemistry, vol. 11, pp. 3185-3202 (2004).
Berkow et al., “The Merck Manual of Medical Information,” pp. 345-350 (1997).
Berkow et al., “The Merck Manual of Medical Information,” pp. 352-355 (1997).
Berkow et al., “The Merck Manual of Medical Information,” pp. 496-500 (1997).
Berkow et al., “The Merck Manual of Medical Information,” pp. 525-526 (1997).
Berkow et al., “The Merck Manual of Medical Information,” pp. 528-530 (1997).
Berkow et al., “The Merck Manual of Medical Information,” pp. 530-532 (1997).
Berkow et al., “The Merck Manual of Medical Information,” pp. 631-634 (1997).
Bevan et al., “Vanilloid Receptors: Pivotal Molecules in Nocciception,”Current Opinions in CPNS Investigational Drugs 2(2): 178-185 (2000).
Chiamulera et al., “Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant rice,”Nature Neuroscience 4(9): 873-874 (2001).
Cooke, “Glycopyrrolate in bladder dysfunction,”SA Medical J. 63:3 (1983).
Dogrul et al., “Peripheral and spinal antihyperalgesic activity of sib-1757, a metabotropic glutamate receptor (muGluR5) antagonist, in experimental neuropathic pain in rats,”Neuroscience Letters 292(2): 115-118 (2000).
Foley, “Pain”Cecil Textbook Of Medicine, pp. 100-107 (1996).
Goodman and Gillman'sThe Pharmaceutical Basis of Therapeutics, pp. 506, 901-915 (J. Hardman and L. Limbird eds., 9thed. 1996).
Herzog et al., “Urinary incontinence: Medical and psychosocial aspects,”Annu. Rev. Gerntol. Geriatr. 9:74-119 (1989).
Kwak et al., “A Capsaicin-Receptor Antagonist, Capsazepine Reduces Inflammation-Induced Hyperalgesic Responses in the Rat: Evidence for an Endogenous Capsaicin-Like Substance,”Neuroscience 86:619-26 (1998).
Levin et al., “Direct Measurement of the Anticholinergic Activity of a Series of Pharacological Compounds on the Canine and Rabbit Urinary Bladder,”J. Urology 128:396-398 (1982).
Lopez-Rodriguez et al., “VRI receptor modulators as potential drugs for neuropathic pain,”Mini Rev. Med. Chem. 3(7): 729-748 (2003).
Mirakhur et al., “Glycopyrrolate: Pharacology and clinical use,”Anaesthesia 38: 1195-1204 (1983).
Ohkubo et al., “The Selective Capsaicin Antagonist Capsazepine Abolishes the Antinociceptive Action of Eugenol and Guaiacol,”J. Dent. Res. 76(4): 848-851 (Apr. 1997).
Ossowska et al., “Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats,”Neuropharmacol. 41:413-420 (2001).
Pan et al., “Soluble Polymer-Supported Synthesis of Arylpiperazines,”Tett. Lett. 39:9505-8 (1998).
Pomonis et al., “N-(4-Tertiarybutylphenyl)-4-(3-chlorphyridin-2-yl)tetrahyropyrazine-1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: II. In vivo characterization in rat models of inflammatory and neuropathic pain,”J Pharmacol Exp Ther. 308(1):387-393 (2003).
Resnick, “Urinary Incontinence,”Lancet 346:94-99 (1995).
Szallasi et al., “Vanilloid (Capsaicin) Receptors and Mechanisma,”Pharmacol. Revs 51(2):159-211 (1999).
Tatarczynska et al., Potential anxiolytic- and antidepressant-like effects of mpep, a potent, selective and systemically active mglu5 receptor antagonist,Brit. J. Pharmacol. 132(7):1423-1430 (2001).
T{dot over (o)}th et al., “Design of a high-affinity competitive antagonist of the vanilloid receptor selective for the calcium entry-linked receptor population,”Mol. Pharmacol. 65(2):282-291 (2004).
Urban et al., “In Vivo Pharmacology of SDZ 249-665, A Novel, Non-pungent Capsaicin Analogue,”Pain 89:65-74 (2000).
Walker et al., “Metabotropic glutamate receptor subtype 5 (mglu5) and nociceptive function. I. Selective blockade of mglu5 receptors in models of acute, persistent and chronic pain,”Neuropharmacol. 40:1-9 (2000).
Wang et al., “High affinity antagonists of the vanilloid receptor,”Mol. Pharmacol. 62(4):947-56 (2002).
Wein, “Pharmacology of incontinence,”Urologic Clinics North Amer. 22(3):557-577 (1995).
Will et al., “Novel allosteric antagonists shed light on mglu5 receptors and CNS disorders,”Trends in Pharmacological Sci. 22(7):331-337 (2001).
Wrigglesworth et al., “Capsaicin-like Agonists,”Drugs of the Future 23(5):531-538 (1998).
Wu et al., “Multiple Sensory and Functional Effects of Non-phenolic Aminodimethylene Nonivamide: An Approach to Capsaicin Antagonist, ”Gen. Pharmac. 27(1):151-158 (1996).

Affiliated with

Also associated with

Rating

Therapeutic agents useful for treating pain does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic agents useful for treating pain, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agents useful for treating pain will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3849285